“…First, existing accounts insufficiently recognise how power and politics shape the governance of new biotechnologies (Harsh & Smith, ). To date, evaluations of policy and regulatory processes of GM crops in Kenya (Kingiri, ) and Uganda (Wafula & Clark, ) suggest that the scientific and technical capacity to evaluate risks of GM crops has been weak but improving, particularly as a result of partnerships with private firms and international organisations. However, as others have pointed out, these relationships are not neutral: ‘Partnerships should be seen for what they are: relationships, often unequal, where each partner strives to serve its own interests first and the outcomes of the partnership second’ (Crewe & Harrison, in Smith, : 651; Harsh, ).…”